TY - JOUR
T1 - Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial
AU - Lund, S.S.
AU - Tarnow, L.
AU - Stehouwer, C.D.A.
AU - Schalkwijk, C.G.
AU - Frandsen, M.
AU - Smidt, U.M.
AU - Pedersen, O.F.
AU - Parving, H.H.
AU - Vaag, A.
PY - 2007/1/1
Y1 - 2007/1/1
N2 - Aim: Metformin is the 'drug-of-first-choice' in obese patients with type 2 diabetes mellitus (T2DM) due to its antihyperglycaemic and cardiovascular protective potentials. In non-obese patients with T2DM, insulin secretagogues are empirically used as first choice. In this investigator-initiated trial, we evaluated the effect of metformin vs. an insulin secretagogue, repaglinide on glycaemic regulation and markers of inflammation and insulin sensitivity in non-obese patients with T2DM. Methods: A single-centre, double-masked, double-dummy, crossover study during 2 x 4 months involved 96 non-obese (body mass index
AB - Aim: Metformin is the 'drug-of-first-choice' in obese patients with type 2 diabetes mellitus (T2DM) due to its antihyperglycaemic and cardiovascular protective potentials. In non-obese patients with T2DM, insulin secretagogues are empirically used as first choice. In this investigator-initiated trial, we evaluated the effect of metformin vs. an insulin secretagogue, repaglinide on glycaemic regulation and markers of inflammation and insulin sensitivity in non-obese patients with T2DM. Methods: A single-centre, double-masked, double-dummy, crossover study during 2 x 4 months involved 96 non-obese (body mass index
U2 - 10.1111/j.1463-1326.2007.00713.x
DO - 10.1111/j.1463-1326.2007.00713.x
M3 - Article
SN - 1462-8902
VL - 9 (3)
SP - 394
EP - 407
JO - Diabetes Obesity & Metabolism
JF - Diabetes Obesity & Metabolism
ER -